DJIA 18,232.02 -53.72 -0.29%
NASDAQ 5,089.36 -1.43 -0.03%
S&P 500 2,126.06 -4.76 -0.22%
market minute promo

Biogen Idec (NASDAQ: BIIB)

398.68 -2.47 (-0.62%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

BIIB $398.68 -0.62%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $399.19
Previous Close $401.15
Daily Range $397.40 - $401.79
52-Week Range $290.85 - $480.18
Market Cap $93.8B
P/E Ratio 28.98
Dividend (Yield) $0.00 (0.0%)
Volume 829,840
Average Daily Volume 1,891,100
Current FY EPS $16.70




Drug Makers

Biogen Idec (BIIB) Description

The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies. Website:

News & Commentary

Healthcare Investment Opportunities for the Long Term

Three healthcare investment opportunities that could be profitable for decades to come.

Stock Market News for May 21, 2015 - Market News

Jim Cramer Answers Your Twitter Questions on Tesla, Jarden, Williams-Sonoma, Wayfair

3 Drugs Stocks Nudging The Industry Higher

5 NASDAQ Healthcare Stocks With The Highest EPS

Stocks End Narrowly Mixed as Oil Closes at May Low

Biosimilars Vs Generics: History Does Not Repeat, It Rhymes

3 Best Biotech Stocks to Add to Your Portfolio

Is Gilead Sciences Its Own Worst Enemy?

Gilead Sciences has an amazing track record of bringing game-changing new drugs to market. Could this unique ability also be the company's biggest weakness?

Buy Microsoft, Biogen for Performance, Avoid Consumer Discretionary Stocks

See More BIIB News...

BIIB's Top Competitors

BIIB $398.68 (-0.62%)
Current stock: BIIB
AMGN $163.59 (-0.15%)
Current stock: AMGN
GILD $111.71 (0.44%)
Current stock: GILD
$0.00 (0.00%)
Current stock: